Summit Therapeutics (SMMT) Competitors $26.13 +2.89 (+12.44%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMMT vs. TAK, ARGX, ONC, BNTX, TEVA, ITCI, GMAB, RDY, MRNA, and VTRSShould you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Takeda Pharmaceutical (TAK), argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Summit Therapeutics vs. Takeda Pharmaceutical argenx Beigene BioNTech Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Summit Therapeutics (NASDAQ:SMMT) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends. Do analysts rate SMMT or TAK? Summit Therapeutics currently has a consensus target price of $35.40, indicating a potential upside of 35.48%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SMMT or TAK more profitable? Takeda Pharmaceutical has a net margin of 4.53% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 9.39% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Takeda Pharmaceutical 4.53%9.39%4.53% Which has higher valuation & earnings, SMMT or TAK? Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K27,536.54-$614.93M-$0.31-84.29Takeda Pharmaceutical$4.58T0.01$994.06M$0.4035.73 Which has more volatility and risk, SMMT or TAK? Summit Therapeutics has a beta of -0.46, indicating that its share price is 146% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Does the MarketBeat Community favor SMMT or TAK? Summit Therapeutics received 207 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 58.44% of users gave Summit Therapeutics an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes30858.44% Underperform Votes21941.56% Takeda PharmaceuticalOutperform Votes10157.06% Underperform Votes7642.94% Do institutionals and insiders believe in SMMT or TAK? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor SMMT or TAK? In the previous week, Summit Therapeutics had 5 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for Summit Therapeutics and 7 mentions for Takeda Pharmaceutical. Summit Therapeutics' average media sentiment score of 0.98 beat Takeda Pharmaceutical's score of 0.49 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTakeda Pharmaceutical beats Summit Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMMT vs. The Competition Export to ExcelMetricSummit TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.28B$6.35B$5.35B$7.58BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-93.326.7721.6817.78Price / Sales27,536.54228.59376.3394.51Price / CashN/A65.6738.1534.64Price / Book237.555.886.443.99Net Income-$614.93M$141.32M$3.20B$247.24M7 Day Performance57.03%8.48%9.01%8.29%1 Month Performance25.69%-12.84%-6.09%-5.37%1 Year Performance614.91%-12.40%10.72%-0.24% Summit Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMMTSummit Therapeutics2.6255 of 5 stars$26.13+12.4%$35.40+35.5%+613.0%$19.28B$700,000.00-93.32110Gap UpHigh Trading VolumeTAKTakeda Pharmaceutical2.3626 of 5 stars$14.37-2.4%N/A+6.9%$45.68B$4.58T35.8947,300Gap UpHigh Trading VolumeARGXargenx3.1269 of 5 stars$549.84-0.9%$687.00+24.9%+60.4%$33.41B$2.19B-624.82650High Trading VolumeONCBeigene2.2846 of 5 stars$221.25-7.2%$310.40+40.3%N/A$21.83B$3.81B-26.8510,600Gap DownBNTXBioNTech2.5187 of 5 stars$86.64-1.6%$143.44+65.6%+18.3%$20.79B$2.75B-41.263,080Gap DownTEVATeva Pharmaceutical Industries3.0106 of 5 stars$13.91+0.8%$23.43+68.5%+2.1%$15.74B$16.54B-9.5836,800Analyst DowngradeOptions VolumePositive NewsITCIIntra-Cellular Therapies3.4982 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsGMABGenmab A/S4.2212 of 5 stars$18.21-1.0%$41.33+127.0%-34.0%$12.05B$21.53B10.461,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.0786 of 5 stars$12.59+1.8%$17.00+35.1%-7.2%$10.48B$311.31B19.9924,800Positive NewsHigh Trading VolumeMRNAModerna4.3313 of 5 stars$25.64+2.1%$59.00+130.1%-74.5%$9.89B$3.20B-2.763,900Positive NewsGap UpVTRSViatris2.9578 of 5 stars$7.61-0.1%$10.50+37.9%-32.7%$9.09B$14.74B-10.2937,000 Remove Ads Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors argenx Competitors Beigene Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Viatris Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SMMT) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SMMT Stock Free SMMT Stock Alerts